{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023158","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.750857+00:00","generated_at":"2026-06-11T14:42:25.872543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Moleculin Biotech Q2 2023 cash $32.2M; 33% CR/CRi in AML trial Phase 1B","bullets":["R&D expense $3.9M, G&A expense $2.5M; cash runway into Q3 2024.","Phase 1B/2 Annamycin monotherapy for soft tissue sarcoma: 73% stable disease after 2 cycles.","Phase 1B portion of Annamycin + Cytarabine for AML completed; 33% CR/CRi rate among 6 patients.","European Phase 1 Annamycin AML results published in British Journal of Cancer Research.","Retained Shareholder Intelligence Services to investigate potential naked short selling."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023158","json":"https://secwatch.observer/filing/0001437749-23-023158.json","markdown":"https://secwatch.observer/filing/0001437749-23-023158.md","text":"https://secwatch.observer/filing/0001437749-23-023158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923023158/0001437749-23-023158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923023158/mbrx20230808c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:42:25.872543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b0e864833f74a856b79591431e1bc00b0edc8f1","claim":"Moleculin Biotech, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 11, 2023, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and recent operational highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923023158/0001437749-23-023158-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}